MX2019000442A - Derivados de etinilo. - Google Patents
Derivados de etinilo.Info
- Publication number
- MX2019000442A MX2019000442A MX2019000442A MX2019000442A MX2019000442A MX 2019000442 A MX2019000442 A MX 2019000442A MX 2019000442 A MX2019000442 A MX 2019000442A MX 2019000442 A MX2019000442 A MX 2019000442A MX 2019000442 A MX2019000442 A MX 2019000442A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- ethynyl derivatives
- emesis
- neuroprotection
- autism
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a los compuestos de las fórmulas lA y IB (ver Fórmulas) o a una sal o sal de adición de ácido farmacéuticamente aceptable, a una mezcla racémica o a su enantiómero y/o isómero óptico y/o al estereoisómero correspondiente de los mismos. Los compuestos pueden usarse en el tratamiento de la enfermedad de Parkinson, la ansiedad, la emesis, el trastorno obsesivo compulsivo, el autismo, la neuroprotección, el cáncer, la depresión y la diabetes del tipo 2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16179837 | 2016-07-18 | ||
| PCT/EP2017/067495 WO2018015235A1 (en) | 2016-07-18 | 2017-07-12 | Ethynyl derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000442A true MX2019000442A (es) | 2019-06-20 |
Family
ID=56418435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000442A MX2019000442A (es) | 2016-07-18 | 2017-07-12 | Derivados de etinilo. |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20190144458A1 (es) |
| EP (1) | EP3484889B1 (es) |
| JP (1) | JP6936305B2 (es) |
| KR (1) | KR20190026805A (es) |
| CN (1) | CN109476671B (es) |
| AR (1) | AR109075A1 (es) |
| AU (1) | AU2017299083B2 (es) |
| BR (1) | BR112019000314A2 (es) |
| CA (1) | CA3030788A1 (es) |
| CL (1) | CL2019000045A1 (es) |
| CO (1) | CO2018013824A2 (es) |
| CR (1) | CR20190014A (es) |
| DK (1) | DK3484889T3 (es) |
| ES (1) | ES2826389T3 (es) |
| HR (1) | HRP20201615T1 (es) |
| HU (1) | HUE051006T2 (es) |
| IL (1) | IL263884A (es) |
| LT (1) | LT3484889T (es) |
| MA (1) | MA45665B1 (es) |
| MX (1) | MX2019000442A (es) |
| PE (1) | PE20190382A1 (es) |
| PH (1) | PH12019500119A1 (es) |
| PL (1) | PL3484889T3 (es) |
| PT (1) | PT3484889T (es) |
| RS (1) | RS60908B1 (es) |
| RU (1) | RU2745068C2 (es) |
| SG (1) | SG11201811829QA (es) |
| SI (1) | SI3484889T1 (es) |
| TW (1) | TWI729169B (es) |
| WO (1) | WO2018015235A1 (es) |
| ZA (1) | ZA201900113B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107580598B (zh) | 2015-07-15 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为代谢型谷氨酸受体调节剂的乙炔基衍生物 |
| CN110183456A (zh) * | 2019-07-11 | 2019-08-30 | 河南师范大学 | 一种2-芳基吲唑琥珀酰亚胺螺环化合物的合成方法 |
| US11515154B2 (en) * | 2020-10-27 | 2022-11-29 | Applied Materials, Inc. | Selective deposition of a passivation film |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003298889A1 (en) * | 2002-12-04 | 2004-06-23 | Merck & Co., Inc. | Spirocyclic ureas, compositions containing such compounds and methods of use |
| UA90145C2 (ru) | 2005-05-24 | 2010-04-12 | Лаборатуар Сероно С.А. | Трициклические спиро-производные как модуляторы crth2 |
| CN101528711A (zh) | 2006-08-31 | 2009-09-09 | 先灵公司 | 可用作抗细菌剂的乙内酰脲衍生物 |
| WO2008151184A1 (en) | 2007-06-03 | 2008-12-11 | Vanderbilt University | Benzamide mglur5 positive allosteric modulators and methods of making and using same |
| WO2011029104A1 (en) | 2009-09-04 | 2011-03-10 | Vanderbilt University | Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8389536B2 (en) | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8586581B2 (en) * | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
| US8420661B2 (en) | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| US8772300B2 (en) | 2011-04-19 | 2014-07-08 | Hoffmann-La Roche Inc. | Phenyl or pyridinyl-ethynyl derivatives |
| HUE025031T2 (en) | 2011-04-26 | 2016-02-29 | Hoffmann La Roche | Ethinyl derivatives as positive allosteric modulators of MGLUR5 |
| US10533000B2 (en) | 2011-05-26 | 2020-01-14 | Sunovion Pharmaceuticals, Inc. | Metabotrophic glutamate receptor 5 modulators and methods of use thereof |
| JP6205354B2 (ja) * | 2011-07-06 | 2017-09-27 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖの処置のための化合物 |
| US20130123254A1 (en) | 2011-09-30 | 2013-05-16 | Barbara Biemans | Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification |
| UA110862C2 (uk) | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
| NZ703537A (en) | 2012-10-18 | 2018-06-29 | Hoffmann La Roche | Ethynyl derivatives |
| SG11201501375YA (en) | 2012-10-18 | 2015-03-30 | Hoffmann La Roche | Ethynyl derivatives as modulators of mglur5 receptor activity |
| CN105121424B (zh) | 2013-02-18 | 2019-01-22 | 华领医药技术（上海）有限公司 | mGluR调节剂 |
| UY35400A (es) | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| DK3049409T3 (en) * | 2013-09-25 | 2017-07-10 | Hoffmann La Roche | ethynyl derivatives |
| TWI649310B (zh) | 2014-01-10 | 2019-02-01 | 赫孚孟拉羅股份公司 | 乙炔基衍生物 |
| AU2015222303B2 (en) | 2014-02-25 | 2019-02-28 | F. Hoffmann-La Roche Ag | Ethynyl derivatives |
| CN104860941B (zh) | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
| WO2016146600A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | 3-(4-ethynylphenyl)hexahydropyrimidin-2,4-dione derivatives as modulators of mglur4 |
| CN107580598B (zh) * | 2015-07-15 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为代谢型谷氨酸受体调节剂的乙炔基衍生物 |
| US10391998B2 (en) | 2016-11-16 | 2019-08-27 | Ford Global Technologies, Llc | Vehicle systems and methods for reducing electrified vehicle noise, vibration, and harshness |
-
2017
- 2017-07-12 PE PE2018003348A patent/PE20190382A1/es unknown
- 2017-07-12 PL PL17742971T patent/PL3484889T3/pl unknown
- 2017-07-12 BR BR112019000314-2A patent/BR112019000314A2/pt not_active IP Right Cessation
- 2017-07-12 SI SI201730468T patent/SI3484889T1/sl unknown
- 2017-07-12 CA CA3030788A patent/CA3030788A1/en not_active Abandoned
- 2017-07-12 PT PT177429719T patent/PT3484889T/pt unknown
- 2017-07-12 SG SG11201811829QA patent/SG11201811829QA/en unknown
- 2017-07-12 KR KR1020197003025A patent/KR20190026805A/ko active IP Right Grant
- 2017-07-12 AU AU2017299083A patent/AU2017299083B2/en not_active Ceased
- 2017-07-12 EP EP17742971.9A patent/EP3484889B1/en active Active
- 2017-07-12 JP JP2019502162A patent/JP6936305B2/ja active Active
- 2017-07-12 LT LTEP17742971.9T patent/LT3484889T/lt unknown
- 2017-07-12 CN CN201780044455.5A patent/CN109476671B/zh active Active
- 2017-07-12 MA MA45665A patent/MA45665B1/fr unknown
- 2017-07-12 HU HUE17742971A patent/HUE051006T2/hu unknown
- 2017-07-12 WO PCT/EP2017/067495 patent/WO2018015235A1/en unknown
- 2017-07-12 RU RU2019102757A patent/RU2745068C2/ru active
- 2017-07-12 ES ES17742971T patent/ES2826389T3/es active Active
- 2017-07-12 MX MX2019000442A patent/MX2019000442A/es active IP Right Grant
- 2017-07-12 CR CR20190014A patent/CR20190014A/es unknown
- 2017-07-12 DK DK17742971.9T patent/DK3484889T3/da active
- 2017-07-12 RS RS20201217A patent/RS60908B1/sr unknown
- 2017-07-17 AR ARP170101987A patent/AR109075A1/es unknown
- 2017-07-17 TW TW106123741A patent/TWI729169B/zh not_active IP Right Cessation
-
2018
- 2018-12-19 CO CONC2018/0013824A patent/CO2018013824A2/es unknown
- 2018-12-20 IL IL263884A patent/IL263884A/en active IP Right Grant
-
2019
- 2019-01-07 CL CL2019000045A patent/CL2019000045A1/es unknown
- 2019-01-08 ZA ZA2019/00113A patent/ZA201900113B/en unknown
- 2019-01-16 PH PH12019500119A patent/PH12019500119A1/en unknown
- 2019-01-17 US US16/250,278 patent/US20190144458A1/en not_active Abandoned
-
2020
- 2020-05-01 US US16/865,233 patent/US11242349B2/en active Active
- 2020-10-08 HR HRP20201615TT patent/HRP20201615T1/hr unknown
-
2022
- 2022-01-04 US US17/568,530 patent/US20220127275A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500106A1 (en) | Ethynyl derivatives as metabotropic glutamate receptor modulators | |
| PH12015502502A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| PH12016501100B1 (en) | Ethynyl-imidazolin-2,4-dione derivatives as mglur4 modulators | |
| IL275585B1 (en) | A process for separating enantiomers of nicotine from a serial mixture | |
| PH12019500119A1 (en) | Ethynyl derivatives | |
| PH12016501863A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| CL2011000137A1 (es) | Uso de compuestos derivados de 4,5-dihidro-oxazol-2-ilamina para tratar trastornos de ansiedad, trastornos bipolar, esquizofrenia, enfermedades neurológicas, epilepsias, migraña, trastornos metabólicos, trastornos cardiovasculares, entre otros; compuestos derivados de 4,5-dihidroxazol-2-ilamino; proceso de síntesis | |
| MX2017008083A (es) | Compuestos 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2h-pirrol-5-amina inhibidores de beta-secretasa. | |
| MA39914A (fr) | Composés hétéroaromatiques et leur utilisation comme ligands de la dopamine d1 | |
| BR112016017816A8 (pt) | derivados de etinila, seus usos, e composição farmacêutica | |
| AR104863A1 (es) | Derivados imidazol | |
| PH12015500346A1 (en) | Ethynyl derivatives as modulators of mglur5 receptor activity | |
| PH12015500496A1 (en) | Ethynyl derivatives as modulators of mglur5 receptor activity | |
| PH12015500261A1 (en) | Arylethynyl pyrimidines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |